Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals' V Oquezna: A Rising Star in GERD Treatment Market
Express News | Phathom Pharmaceuticals Inc - Prices Underwritten Offering at $11.50 per Share
Express News | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Needham analyst Joseph Stringer maintains $Phathom Pharmaceuticals(PHAT.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of 43.8